Results 241 to 250 of about 3,396,679 (311)

Differential cell survival outcomes in response to diverse amino acid stress. [PDF]

Life Sci Alliance
Russier M, Fiore A, Bici A, Groß A, Tanzer M, Yeroslaviz A, Mann M, Murray PJ.   +7 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Integrating 2D dosimetry and cell survival analysis for predicting local effect in spatially fractionated radiotherapy. [PDF]

Acta Oncol
Arous D, Larsen Lie J, Jeppesen Edin NF, Malinen E.   +3 more
europepmc   +1 more source

Measuring the Effect of Newborn Screening on Survival After Hematopoietic Cell Transplantation for Severe Combined Immunodeficiency: A 36-Year Longitudinal Study From the Primary Immune Deficiency Treatment Consortium [PDF]

Trang T. Le, Bird
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Hypoxia response in glioblastoma cells: effect of trehalose on macropinocytosis, autophagy and cell survival. [PDF]

Biochem Biophys Rep
Del Bello B, Ulivieri C, Maellaro E.
europepmc   +1 more source

Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis [PDF]

Robert J. Soiffer, Mitchell E. Horwitz, Joseph P. McGuirk, Sudhindra Rao, Peter Westervelt, John F. DiPersio, Laura Johnston, Jonathan S. Serody, Witold B. Rybka, Paul Shaughnessy, Joseph A. Pidala, Vincent T. Ho, Andrew Artz, Madhuri Vusirikala, David L. Porter, Paul J. Martin, David Avigan, Michael Bishop, Ran Reshef, Andrew C. Peterson, Kwang Wooahn, Adetola A. Kassim, Ryotaro Nakamura, Yi‐Bin Chen, Linda Hammer Burns   +24 more
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Overcoming Sperm Cell Survival Challenges Cryopreserved in Nanoliter Volumes. [PDF]

Int J Mol Sci
Galmidi BS, Orvieto R, Zurgil N, Deutsch M, Fixler D.   +4 more
europepmc   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source